Editas Medicine says its in vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. Editas is shifting focusing to in vivo gene-editing therapies.
The post Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D appeared first on MedCity News.
